An investigational compound called KCL-286 improved the repair of damaged DNA inside neurons and reduced inflammation in a mouse model of Alzheimer's disease, according to research published in FEBS Open Bio. The drug works by switching on the retinoic acid receptor-beta, which sets off a chain of events ending with a protein complex binding to DNA and ramping up the activity of repair genes. Treated animals also showed less neuronal inflammation and less abnormal immune activity in the brain.
The rationale rests on a growing view that accumulated DNA damage in brain cells is not just a byproduct of Alzheimer's but part of what drives it. Jonathan Corcoran, professor of neuroscience at the Institute of Psychiatry, Psychology and Neuroscience at King's College London and corresponding author on the paper, compared the approach to filling potholes in a road: once the surface is fixed, traffic moves again and the whole system calms down. That framing matters because it targets an upstream problem rather than the downstream plaques and tangles most Alzheimer's drugs have gone after.
KCL-286 is further along than most preclinical candidates. Corcoran said phase I trials have already shown a favorable safety profile in humans, which removes one of the usual bottlenecks between animal results and patient testing. The remaining question, and the one the mouse data cannot answer, is whether repairing neuronal DNA translates into cognitive or functional benefit for people living with the disease.
Corcoran said the next step is a trial in patients, contingent on funding, and suggested the same principle could apply to nerve repair and neurodegeneration beyond Alzheimer's. For now, the findings sit squarely in the preclinical stage, where many promising Alzheimer's mechanisms have stalled before.